• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

The Impact of COVID-19 on the HIV Continuum of Care: Challenges, Innovations and Opportunities
Expert Rev Anti Infect Ther. 2023 Jul 20. doi: 10.1080/14787210.2023.2239503. Online ahead of print.ABSTRACTINTRODUCTION: In February 2019, the United States (US) launched the Ending the HIV Epidemic (EHE) initiative with emphasis on improving the various steps of the Human Immunodeficiency Virus (HIV) prevention and care continuum. However, in March 2020, the Coronavirus Disease 2019 (COVID-19) pandemic was declared, curtailing efforts to end the epidemic in the US.AREAS COVERED: To describe the impact of the pandemic on EHE in the US, the authors performed a comprehensive literature review focusing on outcomes at each st...
Source: Expert Review of Anti-Infective Therapy - July 20, 2023 Category: Infectious Diseases Authors: Jenny Yeon Hee Kim Shannon K Barth Anne K Monroe Sarah Ahsan Janja Kovacic Siena Senn Amanda D Castel Source Type: research

Remdesivir for Hospitalized COVID-19 Patients in the United States: Optimization of Health Care Resources
ConclusionsRemdesivir  + SOC alone represents a cost-effective treatment for hospitalized patients with COVID-19. This analysis can aid in future decisions on the allocation of healthcare resources.
Source: Infectious Diseases and Therapy - May 24, 2023 Category: Infectious Diseases Source Type: research

Cost-effectiveness of remdesivir for the treatment of hospitalized patients with COVID-19: a systematic review
ConclusionsBased on the results of the present study, remdesivir appears to be cost-effective in comparison with the standard of care in China, Turkey, and South Africa. Studies conducted in the United States show conflicting results, and combining remdesivir with baricitinib is cost-effective compared with remdesivir alone. However, the cost-effectiveness of remdesivir in low-income countries remains unknown. Thus, more studies in different countries are required to determine the cost-effectiveness of this drug.
Source: Infectious Diseases of Poverty - April 20, 2023 Category: Infectious Diseases Source Type: research

Back to the future of viruses: a case of triple coinfection caused by respiratory syncytial virus, human coronavirus OC43, and rhinovirus
This winter is particularly noteworthy because common viruses are making a resurgence and spreading at an alarming rate, with an unprecedented outbreak of respiratory syncytial virus (RSV) currently ongoing. It is important to remember that RSV can also pose a significant threat to the elderly and those with underlying health conditions [1], which is often overlooked, given the focus on bronchiolitis in healthy children and the associated risk of hospitalization [2]. This is particularly concerning because RSV is believed to be responsible for 14,000 deaths per year in the United States for people aged 65 years and over, a...
Source: International Journal of Infectious Diseases - March 20, 2023 Category: Infectious Diseases Authors: Benjamin Davido, Karim Jaffal, Elyanne Gault, Stephane Bourlet, Sebastien Beaune Tags: Case Report Source Type: research

The Dose- and Time-Dependent Effectiveness and Safety Associated with COVID-19 Vaccination During Pregnancy: A Systematic Review and Meta-analysis
From December 30, 2019, to May 14, 2022, 517,648,631 people were infected with coronavirus disease 2019 (COVID-19), and 6,261,708 people died in total. The male-to-female ratio was 0.9 among infected people and 1.29 in deceased people [1]. According to the U.S. Centers for Disease Control and Prevention (CDC, https://www.cdc.gov/, last accessed 05/09/22), 207,793 pregnant women in the United States were infected, and 296 died.
Source: International Journal of Infectious Diseases - January 24, 2023 Category: Infectious Diseases Authors: Shengyu Wu, Luyao Wang, Jiaqi Dong, Yirong Bao, Xiaohui Liu, Yuhong Li, Xiaohua Liu, Han Xie, Hao Ying Source Type: research

Characteristics and outcomes of US Veterans at least 65 years of age at high risk of severe SARS-CoV-2 infection with or without receipt of oral antiviral agents
Three years into the Covid-19 pandemic, as the end of 2022 approached, deaths attributed to the SARS-CoV-2 coronavirus stood at approximately 6.6 million people globally, including just over 1 million deaths in the United States (US)1. In December of 2020, vaccines were developed that decreased chances of becoming infected and transmitting it to others, and decreased the severity of illness for those still becoming infected2.
Source: Journal of Infection - January 23, 2023 Category: Infectious Diseases Authors: Chris A. Gentry, Phoi Nguyen, Sharanjeet K. Thind, George Kurdgelashvili, Riley J. Williams Tags: Original Article Source Type: research

Impact of COVID-19 pandemic on the epidemiology of other communicable diseases in Japan
The coronavirus disease 2019 (COVID-19) pandemic has affected>600 million patients with over 6.4 million deaths reported globally as of 1 September 2022 [1, 2]. Mortality rates for COVID-19 differ between Western countries (1.1% in the United States, 0.8% in the United Kingdom) and Asian countries (0.5% in China, 0.2% in Japan) [1, 2], although the reasons remain uncertain. National governments have been faced with various challenges in balancing attempts to control the COVID-19 pandemic with stabilization of economic activity.
Source: International Journal of Infectious Diseases - January 12, 2023 Category: Infectious Diseases Authors: Kenji Hirae, Takayuki Hoshina, Hiroshi Koga Source Type: research

A narrative review on drug development for the management of antimicrobial- resistant infection crisis in Japan: the past, present, and future
Expert Rev Anti Infect Ther. 2022 Nov 15:1-13. doi: 10.1080/14787210.2022.2142118. Online ahead of print.ABSTRACTINTRODUCTION: Antimicrobial resistance (AMR) is a major threat to global health requiring continuous development of new antimicrobial agents. Antimicrobial research and development (R&D) should be promoted in the pharmaceutical industry and academia to ensure sustainable patient access to new treatment options and reduce the global AMR burden.AREAS COVERED: This review describes the historical challenges in novel antimicrobial drug development in Japan, current national efforts to promote the development, an...
Source: Expert Review of Anti-Infective Therapy - November 11, 2022 Category: Infectious Diseases Authors: Takahisa Ohashi Masahito Nagashima Nobuko Kawai Norio Ohmagari Kazuhiro Tateda Source Type: research

Updates on Coronavirus Disease 2019 in Children in Japan
This review provides updates on coronavirus disease 2019 (COVID-19) in children in Japan by summarizing published data. By the end of March 2022, Japan had experienced 6 waves of COVID-19 outbreaks. Over this time, the clinical features presented among children have changed in the context of the predominant variants. Although the COVID-19 pandemic affected children in terms of medical, physical and psychosocial aspects, the clinical outcomes have been favorable in Japan compared with those in some European countries and the United States, which may be partly due to a lower incidence of multisystem inflammatory syndromes in...
Source: The Pediatric Infectious Disease Journal - October 19, 2022 Category: Infectious Diseases Tags: Review Articles Source Type: research

PCV13 Pediatric Routine Schedule Completion and Adherence Before and During the COVID-19 Pandemic in the United States
ConclusionsPCV13 full completion was lower during the COVID-19 pandemic compared with pre-pandemic (79.0% vs. 77.1%).
Source: Infectious Diseases and Therapy - October 10, 2022 Category: Infectious Diseases Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20